BTIG Maintains Buy on 89bio, Raises Price Target to $37
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Justin Zelin maintains a 'Buy' rating on 89bio (NASDAQ:ETNB) and raises the price target from $30 to $37.
July 03, 2023 | 9:33 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BTIG analyst maintains a 'Buy' rating on 89bio and raises the price target from $30 to $37, indicating a positive outlook for the stock.
The raised price target by BTIG indicates a positive outlook for 89bio. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100